Elicio Therapeutics, a next generation immuno-oncology company, engineering therapies for cancer killing immune responses, launched today and announced the appointment of Robert Connelly as CEO. Elicio is developing precision vaccines, immuno stimulators and cellular therapies based on the ground-breaking work of Darrell Irvine, PhD., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.

https://elicio.com/2019/03/immuno-oncology-company-elicio-therapeutics-launches-with-novel-vaccine-immunotherapy-platform-to-treat-an-array-of-cancers/